Principal Researcher
Prof. Jamal Mahajna
Plant-based Cancer Drug Discovery
972-50-4242634
Our main interest in the cancer drug discovery program revolves around cancer drug resistance, and in particular, in Ph+ leukemia.
Latest Publications
Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells
2024
Compounds originating from the edible mushroom Auricularia auricula-judae inhibit tropomyosin receptor kinase B activity
Heliyon, e13756
2023
TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer
J Exp Clin Cancer Res, 42(1):107.
doi: 10.1186/s13046-023-02680-7.
doi: 10.1186/s13046-023-02680-7.
2023
Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to OC cells and JAK and c-MET kinase inhibitors restore platinum sensitivity to ovarian cancer cells
Int. J. Mol. Sci. 2023, 24(9), 7730;
2023